{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:41:58Z","timestamp":1791009718260,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T00:00:00Z","timestamp":1223596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12032-008-9100-0","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T12:47:26Z","timestamp":1223556446000},"page":"157-160","source":"Crossref","is-referenced-by-count":48,"title":["Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report"],"prefix":"10.1007","volume":"26","author":[{"given":"Xiao-feng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-xian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-bin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,10]]},"reference":[{"key":"9100_CR1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jjco\/hyd108","volume":"30","author":"Y Nakamura","year":"2000","unstructured":"Nakamura Y, et al. Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma. Jpn J Clin Oncol. 2000;30:385\u20138. doi: 10.1093\/jjco\/hyd108 .","journal-title":"Jpn J Clin Oncol"},{"key":"9100_CR2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00000421-200206000-00012","volume":"25","author":"T Koizumi","year":"2002","unstructured":"Koizumi T, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol. 2002;25:266\u20138. doi: 10.1097\/00000421-200206000-00012 .","journal-title":"Am J Clin Oncol"},{"key":"9100_CR3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F","volume":"67","author":"S Suster","year":"1991","unstructured":"Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 1991;67:1025\u201332. doi:10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F.","journal-title":"Cancer"},{"key":"9100_CR4","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.athoracsur.2005.07.019","volume":"80","author":"AV Bedini","year":"2005","unstructured":"Bedini AV, et al. Proposal of a novel system for the staging of thymic epithelial tumors. Ann Thorac Surg. 2005;80:1994\u20132000. doi: 10.1016\/j.athoracsur.2005.07.019 .","journal-title":"Ann Thorac Surg"},{"key":"9100_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11748-007-0177-8","volume":"56","author":"M Okumura","year":"2008","unstructured":"Okumura M, et al. Clinical and pathological aspects of thymic epithelial tumors. Gen Thorac Cardiovasc Surg. 2008;56:10\u20136. doi: 10.1007\/s11748-007-0177-8 .","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"9100_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-5223(98)70273-9","volume":"115","author":"D Blumberg","year":"1998","unstructured":"Blumberg D, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg. 1998;115:303\u20138. doi: 10.1016\/S0022-5223(98)70273-9 .","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9100_CR7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/JTO.0b013e3181653c71","volume":"3","author":"M Yano","year":"2008","unstructured":"Yano M, et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol. 2008;3:265\u20139. doi: 10.1097\/JTO.0b013e3181653c71 .","journal-title":"J Thorac Oncol"},{"key":"9100_CR8","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1002\/cncr.10588","volume":"94","author":"K Ogawa","year":"2002","unstructured":"Ogawa K, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer. 2002;94:3115\u20139. doi: 10.1002\/cncr.10588 .","journal-title":"Cancer"},{"key":"9100_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/COC.0b013e318042d566","volume":"30","author":"Y Kundel","year":"2007","unstructured":"Kundel Y, et al. Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors. Am J Clin Oncol. 2007;30:389\u201394. doi: 10.1097\/COC.0b013e318042d566 .","journal-title":"Am J Clin Oncol"},{"key":"9100_CR10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cncr.11606","volume":"98","author":"K Yoh","year":"2003","unstructured":"Yoh K, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer. 2003;98:926\u201331. doi: 10.1002\/cncr.11606 .","journal-title":"Cancer"},{"key":"9100_CR11","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","volume":"91","author":"PJ Loehrer Sr","year":"2001","unstructured":"Loehrer PJ Sr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010\u20135. doi:10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2.","journal-title":"Cancer"},{"key":"9100_CR12","first-page":"4851","volume":"26","author":"Y Komatsu","year":"2006","unstructured":"Komatsu Y, et al. Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma\u2014three cases. Anticancer Res. 2006;26:4851\u20135.","journal-title":"Anticancer Res"},{"key":"9100_CR13","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138. doi: 10.1158\/0008-5472.CAN-06-1377 .","journal-title":"Cancer Res"},{"key":"9100_CR14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","volume":"124","author":"M Tomita","year":"2002","unstructured":"Tomita M, et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg. 2002;124:493\u20138. doi: 10.1067\/mtc.2002.124389 .","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9100_CR15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","volume":"130","author":"JD Henley","year":"2004","unstructured":"Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol. 2004;130:222\u20134. doi: 10.1007\/s00432-004-0545-z .","journal-title":"J Cancer Res Clin Oncol"},{"key":"9100_CR16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Str\u00f6bel","year":"2004","unstructured":"Str\u00f6bel P, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004;350:2625\u20136. doi: 10.1056\/NEJM200406173502523 .","journal-title":"N Engl J Med"},{"key":"9100_CR17","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/ijc.23335","volume":"122","author":"V Ehemann","year":"2008","unstructured":"Ehemann V, et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer. 2008;122:2719\u201325. doi: 10.1002\/ijc.23335 .","journal-title":"Int J Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9100-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9100-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:22:35Z","timestamp":1559427755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9100-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,10]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9100"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9100-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,10]]}}}